Panels for myeloproliferative disease – pro
Implementation of amplicon based NGS in diagnosis and molecular classification of MPNs represents an important advancement, as it allows rapid parallel analysis of multiple mutations, detection of clonal hierarchies and clonal evolution as well as molecular monitoring during cytoreductive treatment and targeted therapy of MPNs. NCCN also supports it.
Chang Y et al, Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms.Med Oncol. 2017 May;34(5):83.
Kirschner MMJ, Schemionek M, Schubert C, et al. Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. Mills K, ed. PLoS ONE. 2015;10(4):e0123476.
NCCN, Myeloproliferative 2019, MPN-1